XML 52 R38.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value Considerations (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2020
Fair Value Disclosures [Abstract] |
Fair value on a recurring basis |
| Fair Value Measurements at June 30, 2020
|  | Total |  |  | Quoted Priced in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs(Level 3) |
Recurring: |  |  |  |  |  |  |  |  |  |  |  |
Warrant derivative liability |  | $ | 11,000 |  |  |  | – |  |  |  | – |  |  | $ | 11,000 |
Contingent consideration |  |  | 13,588,000 |  |  |  | – |  |  |  | – |  |  |  | 13,588,000 |
CVR liability |  |  | 5,572,000 |  |  |  | – |  |  |  | – |  |  |  | 5,572,000 |
|  | $ | 19,171,000 |  |  |  | – |  |  |  | – |  |  | $ | 19,171,000 |
| Fair Value Measurements at June 30, 2019
|  | Total |  |  | Quoted Priced in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Recurring: |  |  |  |  |  |  |  |  |  |  |  |
Warrant derivative liability |  | $ | 13,000 |  |  |  | – |  |  |  | – |  |  | $ | 13,000 |
Contingent consideration |  |  | 23,326,000 |  |  |  | – |  |  |  | – |  |  |  | 23,326,000 |
|  | $ | 23,339,000 |  |  |  | – |  |  |  | – |  |  | $ | 23,339,000 |
Significant assumptions in valuing the warrant derivative liability |
|  | As of June 30, 2020 |  |  | As of June 30, 2019 |  |  | At Issuance |
Warrant Derivative Liability |  |  |  |  |  |  |  |  |
Volatility |  |  | 163.2 | % |  |  | 163.2 | % |  |  | 188.0 | %
Equivalent term (years) |  |  | 2.13 |  |  |  | 3.13 |  |  |  | 5.00 |
Risk-free interest rate |  |  | 0.16 | % |  |  | 1.83 | % |  |  | 1.83 | %
Dividend yield |  |  | 0.00 | % |  |  | 0.00 | % |  |  | 0.00 | %
Reconciliation of changes in the warrant derivative liability |
|  | Liability Classified Warrants |
Balance as of June 30, 2018 |  | $ | 94,000 |
Change in fair value included in earnings |  |  | (81,000 | )
Balance as of June 30, 2019 |  | $ | 13,000 |
Change in fair value included in earnings |  |  | (2,000 | )
Balance as of June 30, 2020 |  | $ | 11,000 |
Changes in the contingent consideration |
|  | Contingent Consideration |
Balance as of June 30, 2018 |  | $ | 4,694,000 |
Increase due to purchase of assets |  |  | 8,833,000 |
Increase due to accretion |  |  | 516,000 |
Decrease due to contractual payment |  |  | (548,000 | )
Increase due to remeasurement |  |  | 9,831,000 |
Balance as of June 30, 2019 |  | $ | 23,326,000 |
Increase due to purchase of assets |  |  | 183,000 |
Increase due to accretion |  |  | 789,000 |
Decrease due to contractual payment |  |  | (180,000 | )
Decrease due to amended license agreement |  |  | (5,200,000 | )
Decrease due to remeasurement |  |  | (5,330,000 | )
Balance as of June 30, 2020 |  | $ | 13,588,000 |
Assumption for valuing contingent consideration |
|  | As of June 30, 2020 |  |  | As of June 30, 2019 |
Natesto |  |  |  |  |  |
Relevered Beta |  |  | − |  |  |  | 0.83 |
Market risk premium |  |  | − |  |  |  | 5.50 | %
Risk-free interest rate |  |  | − |  |  |  | 3.50 | %
Discount |  |  | − |  |  |  | 5.20 | %
Company specific discount |  |  | − |  |  |  | 5.00 | %
|  | As of June 30, 2020 |  |  | As of June 30, 2019 |
ZolpiMist |  |  |  |  |  |
Relevered Beta |  |  | 1.17 |  |  |  | 1.16 |
Market risk premium |  |  | 6.00 | % |  |  | 5.50 | %
Risk-free interest rate |  |  | 3.00 | % |  |  | 3.50 | %
Discount |  |  | 5.20 | % |  |  | 5.20 | %
Company specific discount |  |  | 5.00 | % |  |  | 5.00 | %
|  | As of June 30, 2020 |  |  | As of June 30, 2019 |
Tuzistra |  |  |  |  |  |
Relevered Beta |  |  | 0.36 |  |  |  | 1.19 |
Maket risk premium |  |  | 6.00 | % |  |  | 5.50 | %
Risk-free interest rate |  |  | 3.00 | % |  |  | 3.50 | %
Discount |  |  | 5.20 | % |  |  | 5.20 | %
Company specific discount |  |  | 15.00 | % |  |  | 15.00 | %
Fair value on a nonrecurring basis |
|  | Fair Value Measurements at June 30, 2020 |
|  | Fair Value at Measurement Date |  |  | Quoted Priced in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Non-recurring |  |  |  |  |  |  |  |  |  |  |  |
MiOXSYS patent (Luoxis patents) |  | $ | - |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Debt |  |  | 982,079 |  |  |  | - |  |  |  | - |  |  |  | 982,076 |
Pediatric Portfolio (November 1, 2019) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product technology rights |  |  | 22,700,000 |  |  |  | – |  |  |  | – |  |  |  | 22,700,000 |
Goodwill |  |  | 19,453,135 |  |  |  | – |  |  |  | – |  |  |  | 19,453,135 |
Fixed payment arrangements |  |  | 29,837,853 |  |  |  | – |  |  |  | – |  |  |  | 29,837,853 |
Innovus Merger (February 14, 2020) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer lists |  |  | 390,000 |  |  |  | – |  |  |  | – |  |  |  | 390,000 |
Product distribution righs (trademarks and patents) |  |  | 11,354,000 |  |  |  | – |  |  |  | – |  |  |  | 11,354,000 |
Goodwill |  |  | 8,637,272 |  |  |  | – |  |  |  | – |  |  |  | 8,637,272 |
Notes payable |  |  | 3,056,361 |  |  |  | – |  |  |  | – |  |  |  | 3,056,361 |
|  | $ | 96,410,697 |  |  | $ | – |  |  | $ | – |  |  | $ | 96,410,697 |
Significant assumptions in valuing intangible assets |
|  | As of November 1, 2019 (*) |
Product technology rights |  |  |
Re-levered Beta |  |  | 1.60 |
Market risk premium |  |  | 6.00 | %
Small stock risk premium |  |  | 5.20 | %
Risk-free interest rate |  |  | 2.00 | %
Company specific discount |  |  | 25.00 | %
(*) Valuation performed as of November 1, 2019. As a non-recurring fair value measurement, there is no remeasurement at each reporting period unless indications exist that the fair value of the asset has been impaired. There were no indicators as of June 30, 2020 that the fair value of the Product technology rights was impaired.
|  | As of February 14, 2020 |
Trademarks and patents |  |  |
Re-levered Beta |  |  | 0.84 | %
Market risk premium |  |  | 6.17 | %
Small stock risk premium |  |  | 4.99 | %
Risk-free interest rate |  |  | 1.89 | %
Company specific discount |  |  | 20.00 | %
Fixed payment obligations discount rate |
|  | As of November 1, 2019 (≠) |
Fixed payment obligations |  |
Discount rate |  | 1.8% to 12.4% |
(≠) Valuation performed as of November 1, 2019. As a non-recurring fair value measurement, there is no remeasurement at each reporting period unless indicates that the circumstances that existed as of the November 1, 2019 measurement date indicate that the carrying value is no longer indicative of fair value.
Changes in Level 3 inputs |
|  | Product Technology Rights |  |  | Innovus Assets |  |  | Goodwill |  |  | Liability Classified Warrants |  |  | CVR Liability |  |  | Contingent Consideration |  |  | Fixed Payment Arrangements |
Balance as of June 30, 2019 |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | 13,000 |  |  | $ | – |  |  | $ | 23,326,000 |  |  | $ | – |
Transfers into Level 3 |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Transfer out of Level 3 |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Total gains, losses, amortization or accretion in period |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Included in earnings |  |  | (1,513,000 | ) |  |  | (663,000 | ) |  |  | – |  |  |  | (2,000 | ) |  |  | 523,000 |  |  |  | (9,741,000 | ) |  |  | 1,452,000 |
Included in other comprehensive income |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  |  |  |  |  | – |  |  |  |  |
Purchases, issues, sales and settlements |  |  |  |  |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchases |  |  | 22,700,000 |  |  |  | 11,744,000 |  |  |  | 28,090,000 |  |  |  | – |  |  |  | 7,049,000 |  |  |  | 183,000 |  |  |  | – |
Issues |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 29,838,000 |
Sales |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |
Settlements |  |  | – |  |  |  | – |  |  |  | – |  |  |  | – |  |  |  | (2,000,000 | ) |  |  | (180,000 | ) |  |  | (17,778,000 | )
Balance as of June 30, 2020 |  | $ | 21,187,000 |  |  | $ | 11,081,000 |  |  | $ | 28,090,000 |  |  | $ | 11,000 |  |  | $ | 5,572,000 |  |  | $ | 13,588,000 |  |  | $ | 13,512,000 |

X
- References No definition available. + Details
Name: | AYTU_FairValueAssetsAndLiabilitiesUnobservableInputReconciliationTextBlock
Namespace Prefix: | AYTU_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | AYTU_ScheduleOfFixedPaymentObligationsDiscountRateTableTextBlock
Namespace Prefix: | AYTU_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 + Details
Name: | us-gaap_ScheduleOfAssumptionsUsedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration